# Icell Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/icell-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.icell.com.cn
- Latest round: Series A (Dec 15, 2015)
- Investors on record: 2

## About

Based in Shanghai, China and established in 2010, Icell Biotechnology operates as a biotechnology company that focuses on the research and development of cell biotechnology. The company is headquartered in Shanghai and has branches in Beijing, Guangzhou, Chongqing, Hangzhou and Xuzhou. The company has passed the ISO9001 international quality management system certification.

The company’s main business is the research and development of innovative cell therapies and pharmaceuticals. The company’s self-developed products include iCELL™ immune cells and stem cell products, as well as cell therapy technologies such as CIK and DCCIK autologous immune active cells and human amniotic stem cell therapies. Its products are used in the field of regenerative medicine, oncology, and other therapeutic applications.

The company generates revenue by providing cell drug development and manufacturing services, cell medical technology R&D and transformation, and cell preparation and storage services.

## Funding rounds

- Series A, Dec 15, 2015 — Share Capital, Vangoo Capital Partners

## Investors

- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series A
- Vangoo Capital Partners (https://capitalatlas.ai/funds/vangoo-capital-partners) — Series A